X AB (“2cureX” or the “Company”) today announces that it has successfully completed an oversubscribed directed share issue of 6,800,000 shares to a select group of international investors (the ...
Yaqrit Phase 2a data, clinical consensus boost YAQ007 and YAQ006 in Hepatic EncephalopathyStrong global consensus on ...
Expands downstream fermentation capacity to meet growing global demand for pharmaceutical ingredientsMarks the second major investment at the Slovenská Ľupča site in recent yearsFollows the group’s ...
FDA Fast Track Designation granted to 4P004 for the treatment of knee osteoarthritis, recognizing the disease as a serious condition with significant unmet medical need Designation supports enhanced ...
University of Kent researchers reveal that a Centella asiatica compound could combat antibiotic resistant bacteria, offering ...
Report OverviewThe global insulin pumps market is projected to grow at a rate of 12% by 2028, fueled by rising diabetes ...
The global lentiviral vector CDMO market is projected to grow at a CAGR of 8% over the next five years. This growth is driven by rising demand for gene and cell therapies, an expanding pipeline of ...
UPPSALA, SE / ACCESS Newswire / April 22, 2026 / Senzime (STO:SEZI) (OTCQX:SNZZF) - Senzime AB's (publ) interim report for January - March 2026 is now available on the company's website information ...
The randomized Phase 2b ASPIRE trial successfully completed planned enrollment of over 360 patients, reflecting strong execution and robust site engagementASPIRE is designed to assess the effect of ...
Patent grant reinforces long-term US protection of the MET platform underpinning Nanomerics' ocular and nose-to-brain drug delivery pipelines. LONDON, UK / ACCESS Newswire / April 22, 2026 / ...
Late-breaking Phase III FENhance 1 and 2 study results showed superiority of investigational fenebrutinib compared to teriflunomide in reducing relapses and brain lesions in relapsing multiple ...
Ono Pharmaceuticals Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced two upcoming presentations at the 2026 American Society of Clinical Oncology (ASCO) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results